Sign up to save your podcasts
Or
Share Symposium | Sequencing therapies: Optimizing treatment for myelofibrosis
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Symposium | Sequencing therapies: Optimizing treatment for myelofibrosis
This independent educational activity is supported by GSK. All content is developed independently by the faculty; the funder is allowed no influence on the content.
During the European School of Haematalogy (ESH) 4th How to Diagnose and Treat CML/MPN conference, the MPN hub held a symposium on March 9, 2025, titled, Anemia in myelofibrosis: Sequencing therapies to optimize patient outcomes. Here, we share a presentation by Paola Guglielmelli, University of Florence, Florence, IT, discussing the optimal sequencing of therapies in patients with myelofibrosis and anemia.
Guglielmelli discussed the differences between myeloproliferative and cytopenic myelofibrosis (MF), highlighting the limited treatment options in patients with severe cytopenias. She discussed the British Society of Haematology and National Comprehensive Cancer Network guidelines for the treatment of anemia in patients with MF, which both suggest the use of momelotinib in patients with MF and anemia and symptomatic splenomegaly.
Guglielmelli then presented three patient cases and discussed the clinical evidence that influences treatment decisions specific to each case.
Hosted on Acast. See acast.com/privacy for more information.
View all episodes
By Scientific Education Support
3
22 ratings
This independent educational activity is supported by GSK. All content is developed independently by the faculty; the funder is allowed no influence on the content.
During the European School of Haematalogy (ESH) 4th How to Diagnose and Treat CML/MPN conference, the MPN hub held a symposium on March 9, 2025, titled, Anemia in myelofibrosis: Sequencing therapies to optimize patient outcomes. Here, we share a presentation by Paola Guglielmelli, University of Florence, Florence, IT, discussing the optimal sequencing of therapies in patients with myelofibrosis and anemia.
Guglielmelli discussed the differences between myeloproliferative and cytopenic myelofibrosis (MF), highlighting the limited treatment options in patients with severe cytopenias. She discussed the British Society of Haematology and National Comprehensive Cancer Network guidelines for the treatment of anemia in patients with MF, which both suggest the use of momelotinib in patients with MF and anemia and symptomatic splenomegaly.
Guglielmelli then presented three patient cases and discussed the clinical evidence that influences treatment decisions specific to each case.
Hosted on Acast. See acast.com/privacy for more information.